Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James J. Gozzo is active.

Publication


Featured researches published by James J. Gozzo.


Transplantation | 1995

Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine.

William C. Hartner; Willem J. Van der Werf; J. Peter A. Lodge; Brian Gilchrist; Sally R. De Fazio; Thomas G. Markees; Christopher Yatko; Anthony P. Monaco; James J. Gozzo

Rapamycin (Rapa) monotherapy can promote renal allograft survival in dogs, but it is very toxic. To attempt to augment the effectiveness of Rapa and reduce its toxicity in a tolerance induction protocol, canine renal allograft recipients were treated briefly with antilymphocyte serum (ALS), donor bone marrow cells (BMC), and a limited course of cyclosporine (CsA). Rapa had little effect when CsA-treated recipients were given ALS on days -5 to -1 and BMC on day +1. When combined with CsA given days +13 to +42, ALS on days -5 to +7, and BMC on day +10, Rapa at 0.3 mg/kg on day +8 plus alternate days +15 to +39 significantly increased overall survival and was compatible with long-term survival after immunosuppression (6 grafts, 1 graft > 212 days, 1 graft > 470 days). Rapa appeared to prevent early rejections that can occur during treatment with these ALS/BMC/CsA protocols. Little toxicity of Rapa was observed with any treatment.


The Journal of Urology | 1980

Detection of Tumor-Associated Antigens in Urine from Patients with Bladder Cancer

James J. Gozzo; William J. Cronin; Patricia O’brien; Anthony P. Monaco

An antiserum was prepared to a hypotonic saline extract of bladder tumor tissue which, after absorption with normal tissues, was used to localize tumor-associated antigens in a Sephadex G-150 elution profile of urine from patients with bladder cancer. A second antiserum was prepared to the urine fraction with tumor-associated antigens. After absorption with normal urine and plasma this antiserum was reacted in gel diffusion and complement fixation assays against urine samples from normal individuals, patients with bladder cancer and patients with proved urinary tract infections. In the gel diffusion assays none of the 23 urine specimens from normal individuals, 37 per cent of the 24 urine specimens from patients with urinary tract infections, 61 per cent of 13 urine samples from patients with papillomas and in situ tumors, and 95 per cent of 30 samples from patients with bladder cancer gave positive precipitin reactions. In complement fixation assays urine from 53 patients with papillomas through grade IV cancers showed a mean 50 per cent complement fixation at 30 micrograms. protein, 29 patients with urinary tract infections showed a mean 50 per cent complement fixation at 150 micrograms. protein and all but 6 urine specimens from more than 30 normal individuals showed 50 per cent complement fixation (mean value) at 140 micrograms. protein. Thus, an antiserum has been produced that may be used in assays for the diagnosis of bladder cancer.


The Journal of Urology | 1977

Use of Heterogenous and Monospecific Antisera for the Diagnosis of Bladder Cancer

James J. Gozzo; Rita Gottschalk; Patricia O’brien; William J. Cronin; Anthony P. Monaco

A rabbit antibody to antigens present in urine from bladder cancer patients was prepared and used in conjunction with various monospecific antisera to detect urine components related to bladder cancer. All urine samples were centrifuged routinely, dialyzed and concentrated 10 times before assay by gel diffusion versus the various antisera. Urine was considered positive when it showed reactivity with 2 or more antibodies. This method of analysis resulted in the diagnosis of 64% of the bladder papillomas and 77% of the bladder cancers tested, compared to only a 7% falsely positive rate with normal urine. These data support the potential usefulness of an antiserum panel in the immunological diagnosis of bladder cancer in the general population and in high risk individuals.


Transplantation | 1980

Studies On The Mechanism Of Action Of Rabbit Anti-mouse Thymocyte Serum

Simpson Ma; James J. Gozzo

Treatment of B6AF1 (C57BL/6 × A/Jax) mice with either rabbit anti-mouse thymocyte serum (ATS) or with both ATS and sheep red blood cells (SRBCs) resulted in the generation of splenic suppressor cells within 5 days. Suppressor activity was determined by injecting secondary syngeneic recipients with both donor cells and SRBCs. Five days later the SRBCs hemolytic effect of their spleen cells was determined. Suppressor cells were found in either whole spleen or enriched T cell suspensions from mice treated with ATS and SRBCs and in only enriched T cell suspensions from mice treated with ATS alone. These results support the possibility that ATS induces a population of suppressor cells and that these cells may be responsible in part for the immune suppression noted after treatment with ATS.


Annals of Surgery | 1975

Immunological detection of human bladder carcinoma.

Anthony P. Monaco; James J. Gozzo; Robert M. Schlesinger; Codish Sd

A rabbit antiserum (RABCa) to membrane antigenic extracts of human bladder carcinomas was produced. RABCa failed to detect bladder cancer-specific antigens in gel diffusion reactions against antigenic extracts of bladder carcinoma and normal bladder mucosa. However, RABCa showed higher complement fixation activity against urines from bladder cancer patients compared with normal urines. The micro-complement fixation (CF) assay (108 patients) was positive in 17 of 27 bladder cancer patients (62.9%) compared to only 1 of 29 normals (3.4%). However. 10 of 11 patients with urinary infections also were positive. A mocro-Ouchterlony agar gel diffusion assay was also used to study urine samples (118 patients). RABCa produced separate precipitin hands against 20 of 30 bladder cancer urines (66.7%) while only 1 of 24 normal urines gave these bands (4.2%). Again, infected urines were positive (9 of 11). Additionally, urine from patients with benign urological disease was often positive in CF (11 of 41) and Ouchterlony (15 of 43) assays. RABCa serum was absorbed with normal bladder mucosa membrane extracts either once (IX) or three times (3X) to increase the specificity of the Ouchterlony gel diffusion assay. Using RABCa (IX) the per cent of positive bladder cancer urines and normals decreased only slightly, while the number of positive reactions against benign urological disease urines dramatically decreased (17.9%). RABCa (3X) further reduced the per cent of positive reactions with benign urological disease urines (10.3%), greatly reduced the reactivity with infected urines (60.0%), and gave no positive reactions with normal urines, without significantly decreasing the ability to detect bladder carcinoma (51.9%). Althogh RABCa was 100% effective in detecting high grade (III) bladder tumors, almost two-thirds of all transitional cell papilloma urines were also positive. The nature of the material detected in bladder cancer and infected urines by RABCa is probably a product of in vivo inflammation. It does not appear to be part of the bacterial cell membrance or a bacterial metabolite. CEA (up to 10 ng/ml) did not produce positive precipitin bands with RABCa. Sephadex G-100 fractionation of urines suggests that RABCa reacts in the CF and Ouchterlony assays with a component of urine which has a molecular weight greater than 100,000–200,000 M.W. In summary, an antiserum has been prepared which may be used in micro-complement fixation and micro-Ouchterlony agar gel diffusion assays for immunological screening in the early detection of clinical disease, especially bladder cancer and urinary infection.


Transplantation | 1972

Studies on heterologous antilymphocyte serum in mice. Viii. Effect of immunizing cell type and dose on immunosuppressive potency and content of irrelevant antibody.

James J. Gozzo; Mary L. Wood; Anthony P. Monaco

Rabbit antimouse lymphocyte sera (ALS) or antithymocyte sera (ATS) were produced utilizing various lymphoid cell doses in a standard immunization protocol. Sera were assayed in vivo for ability to prolong survival of skin allografts and to suppress antibody formation to sheep erythrocytes (SRBC) or bovine serum albumin (BSA). The immunosuppressive potency of ALS produced with increasing doses of lymph node cells did not increase significantly, although the content of irrelevant antibody to mouse erythrocytes and serum proteins did increase. In contrast, large immunizing doses of thymocytes produced significantly more potent sera than low doses of thymocytes with only minimal increase in content of irrelevant antibody.


Transplantation | 2000

Role of graft interleukin-10 expression in the tolerogenicity of neonatal skin allografts

Sally R. De Fazio; James J. Gozzo

Background. Allografts of skin from neonatal donors survive longer than those from adult donors and can induce tolerance in mice that are treated with short-term immunosuppression. Neonatal (≤24 hr old) epidermal cells (EPC) secrete high levels of interleukin- (IL) 10 and include abundant class II− immature Langerhans cells (LC). In this study, the role of IL-10 in the tolerogenicity of neonatal skin grafts was examined. Methods. After a preliminary experiment established that tolerogenesis by neonatal grafts could be supported by monoclonal antilymphocyte antibodies, B10.A(5R) recipients were immunosuppressed with anti-CD4 plus anti-CD8 (days 0, +2) and adult C57Bl/6 bone marrow cells (day +7). Recipients were grafted with adult or neonatal C57Bl/6 skin from wild-type or IL-10 deficient (“knockout” donors). EPC from wild-type and knockout neonatal skin were compared by flow cytometry, before and after 48 hr culture, to adult cells in terms of class II and costimulatory molecule expression. Results. Grafts from knockout neonates survived longer than those from adult donors (median survival, MST=81 vs. 61 days), but not as long as those from wild-type neonates (MST=100 days;P <0.05). As with normal neonatal EPC, neonatal knockout EPC expressed little class II antigen. Both types of neonatal EPC acquired class II in culture, and up-regulated CD80 and CD86 in an adult pattern, but failed to up-regulate class II antigen to the high level seen among cultured adult cells. Conclusions. The tolerogenicity of neonatal skin grafts derives in part from natural expression of IL-10 by the graft. Another possible contribution to tolerogenicity may be the inability of neonatal antigen presenting cells to up-regulate class II fully. Low expression of class II by neonatal cells is not attributable to epidermal IL-10 secretion.


The Journal of Urology | 1980

Urinary Proteins as Biological Markers: Bladder Cancer Diagnosis Versus Urinary Tract Infection

Patricia O’brien; James J. Gozzo; Anthony P. Monaco

Urine specimens from normal individuals, and from patients with bladder cancer, bladder papillomas and urinary tract infections were assayed for the presence of bladder tumor-related antigens. Ten-fold concentrated urine specimens were reacted in Ouchterlony gel diffusion against various anti-human monospecific antisera. With these antisera urine specimens from normal individuals were distinguished from those from patients with bladder carcinoma as well as bladder papilloma. However, the urine samples from individuals with urinary tract infections showed significant reactivity with many of the monospecific antisera as did specimens from patients with bladder cancer and bladder papilloma. Thus, investigations involved in the assay of bladder cancer biological markers should take the proteinuria associated with urinary tract infection into consideration. The potential importance of detecting tumor-specific components for early diagnosis and treatment of bladder neoplasms is stressed.


Transplantation | 1972

Studies on heterologous antilymphocyte serum in mice. IX. In vitro assay by indirect leukoagglutination.

James J. Gozzo; Mary L. Wood; Anthony P. Monaco

Eighteen rabbit antimouse lymphocyte sera (ALS) or thymocyte sera (ATS) were prepared by a standard immunization protocol and tested for their immunosuppressive ability to prolong skin allografts. In vitro cytotoxicity and direct leukoagglutination titers showed little correlation with immunosuppressive ability of the various sera. The capacity of individual sera to facilitate in vivo opsonization of rabbit ALS-or ATS-coated lymphocytes or thymocytes in syngeneic hosts showed a moderately good correlation with immunosuppressive ability. This study describes a simple, reproducible, in vitro indirect leukoagglutination assay for detecting antilymphocyte or antithymocyte globulin bound to lymphocytes or thymocytes using a specific goat antirabbit IgG (GARIgG) serum. Bound (indirect) IgG end point titers correlated extremely well with in vivo immunosuppressive ability. In contrast to opsonization assays in which the requirement of in vivo opsonization limits their potential usefulness for assay of antihuman lymphocyte sera, in vitro indirect leukoagglutination should be readily applicable to human ALS preparations.


Transplantation | 1969

A NEW METHOD FOR THE PRODUCTION OF RABBIT ANTIRAT LYMPHOCYTE SERUM

James J. Gozzo; Allyn H. Rule; Joseph P. Gentile

SUMMARY Rat lymphocytes, chemically cross linked with 1,5-difluoro-2,4-dinitrobenzene, when injected into rabbits, produced an antilymphocyte serum that was more avid and specific for lymphocytes as shown by several in vitro and in vivo systems than was antilymphocyte serum produced by standard methods. Chemically treated lymphocytes did not lyse in distilled water and, after prolonged storage at 4 C, did not show any change in antigenicity. Electron micrographs of treated lymphocytes and thymocytes, stored as long as 6 months at 4 C, showed little or no difference when compared to untreated cells obtained within 24 hr

Collaboration


Dive into the James J. Gozzo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Patricia O’brien

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

William J. Cronin

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takashi Maki

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rita Gottschalk

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sally R. DeFazio

Beth Israel Deaconess Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge